Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

But how do these microbial communities work? And can we harness their power to make agriculture more sustainable? These ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous ...

Roche is meanwhile tying up with Denmark's Zealand Pharma to invent a better GLP-1 weigh-loss drug. Despite these developments, Novo Nordisk stock remains the most attractively valued GLP-1 ...

American demand for weight-loss drugs is supercharging Denmark’s economy and transforming a small Danish community into an unlikely boomtown.